A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma.

Trial Profile

A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2015

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00420381).
    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00420381).
    • 26 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov (NCT00420381).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top